Management Indicators Not Established as the Company Has Not Yet Obtained Marketing Approval
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: 2026-03-27.
2 other companies' latest entry also says "Restated".
- 2026-03-27RestatedManagement Planning
「We will first pursue the early domestic launch of the world's first iPS cell-derived cardiac muscle sphere product, followed by global expansion of minimally invasive catheter-based administration.」
Before obtaining approval, the Company reaffirmed its plan to pursue the domestic launch of HS-001 first, followed by overseas expansion of HS-005. - FY2025RestatedAnnual report
「The Company is currently a research-stage company and does not have any products that have received marketing approval. At this stage, we are pursuing early commercialization centered on the lead pipeline while monitoring progress in R&D and clinical trials and the balance between R&D funding and expenses.」
The Company remains pre-approval and is monitoring development progress and the balance between R&D funding and expenses without setting target management metrics. - FY2024First statedAnnual report
「The Company is currently a research-stage company and does not have any products that have received marketing approval. Although development milestone income received from Novo Nordisk A/S based on development progress is recognized as revenue, it is highly uncertain, and therefore the Company has not established target management metrics or other benchmarks.」
As a pre-approval R&D company, the Company has not established management metrics because of the uncertainty of development milestone income.